AstraZeneca PLC - Product Pipeline Review - 2014 - KTUL.com - Tulsa, Oklahoma - News, Weather & Sports

AstraZeneca PLC - Product Pipeline Review - 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, July 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

AstraZeneca PLC - Product Pipeline Review - 2014

http://www.reportbuyer.com/computing_electronics/manufacturing/astrazeneca_plc_product_pipeline_review_2013.html

AstraZeneca PLC - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AstraZeneca PLC - Product Pipeline Review - 2014', provides an overview of the AstraZeneca PLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AstraZeneca PLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AstraZeneca PLC including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of AstraZeneca PLC's human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the AstraZeneca PLC's pipeline products

Reasons to buy

- Evaluate AstraZeneca PLC's strategic position with total access to detailed information on its product pipeline- Assess the growth potential of AstraZeneca PLC in its therapy areas of focus- Identify new drug targets and therapeutic classes in the AstraZeneca PLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of AstraZeneca PLC and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AstraZeneca PLC- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of AstraZeneca PLC and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issuesTable of Contents

AstraZeneca PLC Snapshot 7

AstraZeneca PLC Overview 7

Key Information 7

Key Facts 7

AstraZeneca PLC - Research and Development Overview 8

Key Therapeutic Areas 8

AstraZeneca PLC - Pipeline Review 19

Pipeline Products by Stage of Development 19

Pipeline Products - Monotherapy 20

Pipeline Products - Combination Treatment Modalities 21

Pipeline Products - Partnered Products 22

Pipeline Products - Out-Licensed Products 25

AstraZeneca PLC - Pipeline Products Glance 27

AstraZeneca PLC - Late Stage Pipeline Products 27

AstraZeneca PLC - Clinical Stage Pipeline Products 31

AstraZeneca PLC - Early Stage Pipeline Products 37

AstraZeneca PLC - Drug Profiles 41

(dapagliflozin + metformin hydrochloride) XR 41

(saxagliptin + metformin hydrochloride) 43

cangrelor 45

dapagliflozin 47

naloxegol 50

olaparib 52

ticagrelor 54

vandetanib 57

(budesonide + formoterol) 63

(ceftazidime + avibactam) 64

(glycopyrrolate + formoterol fumarate) 66

(saxagliptin + dapagliflozin) 68

AZD-9291 69

budesonide ER 70

ceftaroline fosamil 72

fulvestrant 74

gefitinib 76

glycopyrrolate 81

lesinurad 82

metreleptin 84

propofol 86

PT-005 87

quetiapine fumarate ER 89

selumetinib sulfate 90

tenapanor 93

(ceftaroline + avibactam) 95

AZD-1775 97

AZD-1981 99

AZD-2014 100

AZD-2115 101

AZD-3241 102

AZD-4017 103

AZD-4547 105

AZD-4901 106

AZD-5069 107

AZD-5213 108

AZD-5363 109

AZD-5847 111

AZD-9150 113

DSP-3025 114

exenatide Once Monthly 116

HMPL-504 118

Omega-3-carboxylic acids 120

PT-008 122

RDEA-3170 123

saracatinib 124

AZD-1480 126

sapitinib 127

(glycopyrrolate + formoterol fumarate + budesonide) 129

AZD-0424 131

AZD-0914 132

AZD-1208 133

AZD-1979 135

AZD-3293 136

AZD-3965 137

AZD-4721 138

AZD-5312 139

AZD-6423 140

AZD-6738 141

AZD-7451 142

AZD-7624 143

AZD-8186 144

BMS-820132 145

disufenton sodium 146

MEDI-1814 149

MEDI-4893 150

MEDI-8111 152

PEG-FGF21 153

264-RAD 154

900 Series 155

AC-163794 156

AR-A-014418 157

AZ-1 158

AZ-12441970 159

AZ-2 160

AZ-4217 161

AZ-4425 162

AZ-64 163

AZ-709 164

AZ-876 165

AZ-889 166

AZD-2098 167

AZD-2858 168

AZD-3463 169

AZD-9708 170

Drug 1 for Cancer 171

Drug 2 for Cancer 172

Drug 3 for Cancer 173

Drug 4 for Cancer 174

Drug 5 for Cancer 175

Drug 6 for Cancer 176

KU-0060648 177

KU-59403 178

NKTR-119 179

Program 1 for Cancer 180

Program 2 for Cancer 181

pyrrolamide-4 182

R-256 183

RDEA-684 184

Small Molecule to Agonize Melanocortin 4 Receptor for Metabolic Disorders 185

Small Molecule to Inhibit PI3K Beta for Clotting Disorders 186

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia 187

Small Molecules for Malaria 188

Small Molecules to Antagonize P2X3 for Chronic Pain 189

Small molecules To Inhibit CDK9 for Central Nervous System and Immunology 190

Small Molecules to Inhibit DNA GyrB for Tuberculosis 191

Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis 192

XL-475 193

Aminopyrazinamides 194

AZ-10047130 195

AZ-10776241 196

AZ-82 197

AZD-2738 198

Drugs for Cardiovascular Diseases 199

Drugs for Multi Drug Resistant Tuberculosis 200

Fosmidomycin Analogues 201

Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis 202

Small Molecules for Tuberculosis 203

Small Molecules to Induce Senescence for Cancer 204

Small Molecules to Inhibit ATP Synthesis for Tuberculosis 205

AstraZeneca PLC - Pipeline Analysis 206

AstraZeneca PLC - Pipeline Products by Target 206

AstraZeneca PLC - Pipeline Products by Route of Administration 213

AstraZeneca PLC - Pipeline Products by Molecule Type 214

AstraZeneca PLC - Pipeline Products by Mechanism of Action 215

AstraZeneca PLC - Recent Pipeline Updates 222

AstraZeneca PLC - Dormant Projects 273

AstraZeneca PLC - Discontinued Pipeline Products 280

Discontinued Pipeline Product Profiles 285

AstraZeneca PLC - Company Statement 307

AstraZeneca PLC - Locations And Subsidiaries 309

Head Office 309

Other Locations & Subsidiaries 309

AstraZeneca PLC - Key Manufacturing Facilities 314

Appendix 315

Methodology 315

Coverage 315

Secondary Research 315

Primary Research 315

Expert Panel Validation 315

Contact Us 316

Disclaimer 316

List of Tables

AstraZeneca PLC, Key Information 19AstraZeneca PLC, Key Facts 19AstraZeneca PLC - Pipeline by Indication, 2014 22AstraZeneca PLC - Pipeline by Stage of Development, 2014 31AstraZeneca PLC - Monotherapy Products in Pipeline, 2014 32AstraZeneca PLC - Combination Treatment Modalities in Pipeline, 2014 33AstraZeneca PLC - Partnered Products in Pipeline, 2014 34AstraZeneca PLC - Partnered Products/ Combination Treatment Modalities, 2014 35AstraZeneca PLC - Out-Licensed Products in Pipeline, 2014 37AstraZeneca PLC - Out-Licensed Products/ Combination Treatment Modalities, 2014 38AstraZeneca PLC - Pre-Registration, 2014 39AstraZeneca PLC - Filing rejected/Withdrawn, 2014 40AstraZeneca PLC - Phase III, 2014 41AstraZeneca PLC - Phase II, 2014 43AstraZeneca PLC - Phase I, 2014 46AstraZeneca PLC - Preclinical, 2014 49AstraZeneca PLC - Discovery, 2014 52AstraZeneca PLC - Pipeline by Target, 2014 219AstraZeneca PLC - Pipeline by Route of Administration, 2014 225AstraZeneca PLC - Pipeline by Molecule Type, 2014 226AstraZeneca PLC - Pipeline Products by Mechanism of Action, 2014 228AstraZeneca PLC - Recent Pipeline Updates, 2014 234AstraZeneca PLC - Dormant Developmental Projects,2014 285AstraZeneca PLC - Discontinued Pipeline Products, 2014 292AstraZeneca PLC, Subsidiaries 321AstraZeneca PLC, Key Manufacturing Facilities 326

List of Figures

AstraZeneca PLC - Pipeline by Top 10 Indication, 2014 22

AstraZeneca PLC - Pipeline by Stage of Development, 2014 31

AstraZeneca PLC - Monotherapy Products in Pipeline, 2014 32

AstraZeneca PLC - Combination Treatment Modalities in Pipeline, 2014 33

AstraZeneca PLC - Partnered Products in Pipeline, 2014 34

AstraZeneca PLC - Out-Licensed Products in Pipeline, 2014 37

AstraZeneca PLC - Pipeline by Top 10 Target, 2014 218

AstraZeneca PLC - Pipeline by Top 10 Route of Administration, 2014 225

AstraZeneca PLC - Pipeline by Top 10 Molecule Type, 2014 226

AstraZeneca PLC - Pipeline Products by Top 10 Mechanism of Action, 2014 227

Companies Mentioned

Read the full report:

AstraZeneca PLC - Product Pipeline Review - 2014

http://www.reportbuyer.com/computing_electronics/manufacturing/astrazeneca_plc_product_pipeline_review_2013.html

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

P.O. Box 8 Tulsa, OK 74101-0008

Powered by WorldNow

All content © Copyright 2000 - 2014 Worldnow and KTUL. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.